Literature DB >> 1974439

The pharmacology of fenoldopam.

A J Nichols1, R R Ruffolo, D P Brooks.   

Abstract

Fenoldopam is a selective dopamine1 (DA1) receptor agonist. Most of the DA1 receptor agonist activity of fenoldopam resides in the R-enantiomer, which also shows weaker alpha 2-adrenoceptor antagonist activity Fenoldopam produces vasodilation in vascular beds that are rich in vascular DA1 receptors, eg, renal and mesenteric receptors, and produces an increase in renal blood flow at doses that do not affect blood pressure. At higher doses, fenoldopam lowers blood pressure but still maintains renal perfusion. In addition to its renal vasodilator activity, fenoldopam is natriuretic, possibly resulting from a direct effect of DA1 receptors on the proximal convoluted tubule. In animals with spontaneous or drug-induced renal failure, fenoldopam improves renal function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974439     DOI: 10.1093/ajh/3.6.116s

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

Authors:  Jennie L Conroy; R Benjamin Free; David R Sibley
Journal:  ACS Chem Neurosci       Date:  2015-02-20       Impact factor: 4.418

Review 2.  Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors.

Authors:  Jaromir Myslivecek
Journal:  Life (Basel)       Date:  2022-04-19

3.  Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta.

Authors:  Veronica Zingales; Sebastiano Alfio Torrisi; Gian Marco Leggio; Claudio Bucolo; Filippo Drago; Salvatore Salomone
Journal:  Biomolecules       Date:  2021-03-11

Review 4.  Future insights of pharmacological prevention for AKI post cardiopulmonary bypass surgery (based on PK/PD approach).

Authors:  Dias Permeisari
Journal:  Front Pharmacol       Date:  2022-09-22       Impact factor: 5.988

5.  A positive-negative switching LC-MS/MS method for quantification of fenoldopam and its phase II metabolites: Applications to a pharmacokinetic study in rats.

Authors:  Ting Du; Rongjin Sun; Nyma Siddiqui; Linda Moatamed; Yun Zhang; Dong Liang; Ming Hu; Song Gao
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2021-07-05       Impact factor: 3.318

Review 6.  Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis.

Authors:  Michael A Gillies; Vivek Kakar; Robert J Parker; Patrick M Honoré; Marlies Ostermann
Journal:  Crit Care       Date:  2015-12-25       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.